Roche clinches EU approval for MabThera in rare autoimmune indication — will it boost dwindling sales amid biosimiar competition?

Roche is piling up another European approval for its MabThera franchise just as biosimilars are seriously eroding sales of the crucial drug, better known in the US as Rituxan.